



World Health
Organization

Member States Briefing – Allocation Round Results

February 25th 2021

WHO Emergency Use Listing (EUL) – review timelines

31st December: Pfizer/BioNTech

15th February: AZ/Serum Institute of India
AZ/SK Bio, Republic of Korea

End Feb: Moderna

March: Sinopharm BIBP
Sinovac
J&J*

In discussion: Gamaleya
Novavax

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

Manufacturer	Name of Vaccine	Regulatory Authority	Platform	EDL accepted	Pre-submission meeting held	Decision accepted for review*	Status of assessment**	Anticipated decision date***
	BNT162b2/COMIRNATY Tozinameran (mRNA)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/12/20
	AZD1222	Core - EMA Non-COVAX	Recombinant (rAd5) adenoviral vector encoding the spike protein antigen of the SARS-CoV-2	✓	✓	Accepted core data of AZ - non-COVAX	Non-COVAX Core data	NA
	AZD1222	MFSD KOREA	Recombinant (rAd5) adenoviral vector encoding the spike protein antigen of the SARS-CoV-2	✓	✓	Data for Core expected in March 2021	Assessed	March - April 2021
	CoVishield (CNANON1_nCoV-19)	DCGI	Recombinant (rAd5) adenoviral vector encoding the spike protein antigen of the SARS-CoV-2	✓	✓	✓	Assessment in progress in consultation with MFSD	Mid Feb 2021
	SARS-CoV-2 Vaccine (Vero Cells), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	In progress	Earliest March
	SARS-CoV-2 Vaccine (Vero Cells), Inactivated	NMPA	Inactivated, produced in Vero cells	✓	✓	Additional expected end of Feb 2021	In progress	Earliest March
	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticles (LNPs)	✓	✓	Additional data expected on 13 Feb 2021	In progress	Estimated end of Feb 2021
	Ad5-Ad26.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	Rolling data to EMA - Dec. 28 Jan 27 th half Feb 2021	Not yet started	March - April 2021
	Sputnik V	Russian NMA	Human Adenovirus Vector-based COVID-19 vaccine	Additional submission submitted	Several meetings held	Rolling data expected 09 and 13 Feb 2021	Use abridged procedure relying on EMA	

<https://extranet.who.int/pqweb/key-resources/documents/status-covid-19-vaccines-within-who-eulpq-evaluation-process>
https://extranet.who.int/pqweb/sites/default/files/documents/Product-Eligibility_COVAX-Facility_Dec2020_0.pdf

* Abridged procedure - EMA

Overview of the timeline and scope of the current allocation round

Allocation round scope

- **Volumes in scope:**
 - Jan-May volumes for SII and AZ
- **Output of the allocation**
 - Allocated volume per vaccine per participant for the whole round
 - AZ/SII doses from Jan (only India¹) to May
 - A pro-rated cap for Feb¹-March doses (proportional to the monthly supply for all participants) to allow for all ready participants to place POs aiming for March shipments


Key statistics

- **142** participants allocated
- Total allocated volume this round is **237M** doses
- Overall weighted average coverage (all vaccines of this round): **2.46%**

¹ And voluntarily capped at 50M doses over the Feb-May period

Pending supply availability confirmation

Update on the AZ and SII allocation round - Overview of the supply



5% of the total Jan-May volume will be dedicated to the COVAX Buffer, but has been taken from the April-May volume

Sequencing of delivery

- The Allocation will also include a stratified prioritization list for delivery sequence, ensuring balance between regions and income level, with the aim to have doses for all prepared participants by end of March
- Based on that, shipments will be sequenced taking into account preparedness, logistics, flights and freight forwarders (*see below for indicative process*)



Next steps

- **Friday Feb 25th (tbc)** - Detailed allocation outcomes will be shared with all participants (pending alignment with COVAX partners)
- Upon communication of the allocation outcomes, participants will be invited to place POs first for their Feb-March volumes, then for their April-May volumes
- **Monday Mar 1st** – COVAX Press event to release the results of the Allocation
- The next allocation round will be triggered upon EUL of a new vaccine in the COVAX portfolio with secured supply